Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.

By C. Bokemeyer, I. Bondarenko, J. Hartmann, F. D. Braud, G. Schuch, A. Zubel, I. Celik, M. Schlichting, P. Koralewski. Annals of Oncology, 2011

813 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, background): “Studies involving the retrospective analysis of RR (specifically in patients with liver-limited disease) and the corresponding R0 resection rates provide additional information [44, 46, 183, 184], but need to be regarded with caution.”
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. (2013, neutral): “Worst grade of 5 14 (5) 16 (6) 30 (6) 19 (7) 10 (4) 29 (5)”
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials † (2017, background): “Independent from tumour localization, RAS mutant tumour status is known to be a very strong negative predictor for EGFR antibody therapy whilst, RAS wt tumour status is a relatively strong predictive marker for the efficacy of EGFR antibody therapy [43, 45, 46, 58].”
Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. (2015, result): “However, it was reported that for patients with KRAS exon 2 tumor mutations, the addition of cetuximab to FOLFOX4 resulted in worse outcome compared with FOLFOX4 alone.(3,4) Similar findings were also reported from the PRIME (Panitumumab Randomized Trial in Combination With Chemotherapy for Metastat”